These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21851800)

  • 21. Regulatory innovation in postmarketing risk assessment and management.
    Staffa JA; Dal Pan GJ
    Clin Pharmacol Ther; 2012 Mar; 91(3):555-7. PubMed ID: 22297386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 23. [Novel therapeutics risk management].
    Hagemann U
    Z Evid Fortbild Qual Gesundhwes; 2009; 103(5):269-72. PubMed ID: 19645340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current French system of post-marketing drug surveillance.
    Albengres E; Gauthier F; Tillement JP
    Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):312-4. PubMed ID: 2387656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-approval drug research: objectives and methods.
    Schäfer H
    Pharmacopsychiatry; 1997 Jan; 30(1 Suppl):4-8. PubMed ID: 9035222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmaceutical risk management in Turkey: the first national overview.
    Aydinkarahaliloglu ND; Aykac E; Kasap Y; Durmus N; Babacanoglu C; Basgut CE; Artiran G; Kerman S
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):344-50. PubMed ID: 23994623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Post-marketing surveillance systems for psychoactive prescription drug abuse].
    Nordmann S; Frauger E; Pauly V; Rouby F; Mallaret M; Micallef J; Thirion X
    Therapie; 2011; 66(3):263-72. PubMed ID: 21819810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The safety of drugs].
    de Cea Lavech de Chancy H
    Rev Clin Esp; 1990 Sep; 187(4):184-90. PubMed ID: 2091076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives.
    Leong J; McAuslane N; Walker S; Salek S
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):1004-12. PubMed ID: 23740622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drug monitoring].
    Royer RJ
    Bull Soc Ophtalmol Fr; 1985 Nov; Spec No():11-30. PubMed ID: 4064240
    [No Abstract]   [Full Text] [Related]  

  • 32. Collection and analysis of drug safety data in pregnancy.
    Moretti M
    Can J Clin Pharmacol; 2007; 14(1):e34-6. PubMed ID: 17213508
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety in numbers--monitoring risk in approved drugs.
    Okie S
    N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract]   [Full Text] [Related]  

  • 34. Opening Pandora's pillbox: using modern information tools to improve drug safety.
    Gottlieb S
    Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.
    Borer JS; Pouleur H; Abadie E; Follath F; Wittes J; Pfeffer MA; Pitt B; Zannad F
    Eur Heart J; 2007 Aug; 28(15):1904-9. PubMed ID: 17615083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)].
    Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The regulatory view on drug-drug interactions.
    Müller HJ; Gundert-Remy U
    Int J Clin Pharmacol Ther; 1994 Jun; 32(6):269-73. PubMed ID: 7921523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Guidance of FDA risk evaluation and mitigation strategy and enlightenment to drug risk management of post-marketing Chinese medicine].
    Li Y; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2825-7. PubMed ID: 22292376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The licensing of medicines in the UK.
    Drug Ther Bull; 2009 Apr; 47(4):45-8. PubMed ID: 19357299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.